Moomoo AIのまとめ
On May 21, 2024, Invivyd, Inc., a biopharmaceutical company, held its Annual Meeting of Stockholders where seven directors were elected for a one-year term. The elected directors include Tamsin Berry, Sara Cotter, Marc Elia, Srishti Gupta, M.D., Christine Lindenboom, Terrance McGuire, and Kevin McLaughlin. Additionally, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Following the meeting, Invivyd issued a press release announcing the election of two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, who will serve as Chairpersons of the Compensation and Audit Committees, respectively. The company expressed its enthusiasm for the expertise the new directors will bring during a period of...Show More
On May 21, 2024, Invivyd, Inc., a biopharmaceutical company, held its Annual Meeting of Stockholders where seven directors were elected for a one-year term. The elected directors include Tamsin Berry, Sara Cotter, Marc Elia, Srishti Gupta, M.D., Christine Lindenboom, Terrance McGuire, and Kevin McLaughlin. Additionally, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Following the meeting, Invivyd issued a press release announcing the election of two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, who will serve as Chairpersons of the Compensation and Audit Committees, respectively. The company expressed its enthusiasm for the expertise the new directors will bring during a period of growth, particularly as Invivyd commercializes its first product and advances its proprietary tools for variant analysis and predictive modeling. The press release also highlighted the recent emergency use authorization (EUA) granted by the U.S. FDA for Invivyd's monoclonal antibody for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals, marking a significant milestone for the company.
2024年5月21日、バイオ製薬会社であるInvivyd社は、1年の任期で7人の取締役が選出された株主総会を開催しました。当選した取締役には、Tamsin Berry、Sara Cotter、Marc Elia、Srishti Gupta、M.D.、Christine Lindenboom、Terrance McGuire、Kevin McLaughlinが含まれています。さらに、株主は2024年12月31日までの決算年度において、PricewaterhouseCoopers LLPを同社の独立登録会計士として承認しました。会合後、Invivyd社は、新たに2人の独立取締役、Dr. Srish...すべて展開
2024年5月21日、バイオ製薬会社であるInvivyd社は、1年の任期で7人の取締役が選出された株主総会を開催しました。当選した取締役には、Tamsin Berry、Sara Cotter、Marc Elia、Srishti Gupta、M.D.、Christine Lindenboom、Terrance McGuire、Kevin McLaughlinが含まれています。さらに、株主は2024年12月31日までの決算年度において、PricewaterhouseCoopers LLPを同社の独立登録会計士として承認しました。会合後、Invivyd社は、新たに2人の独立取締役、Dr. Srishti GuptaとKevin F. McLaughlinの選出を発表し、それぞれ報酬委員会と監査委員会の議長を務めます。同社は新たな取締役が成長期に特にInvivyd社が初めての製品を商品化し、変異解析および予測モデリングのための特許技術を進める中でもたらす専門的知見に熱狂しています。プレスリリースはまた、免疫不全患者のCOVID-19事前暴露予防のためのInvivyd社のモノクローナル抗体に対する米国FDAの緊急使用許可（EUA）が最近付与されたことを強調し、同社にとって重要なマイルストーンであることを示しました。
役に立った
役に立たない
